Inflammatory bowel disease Disease progression Acceptability Over 80s Monitoring HIV Safety Colon cancer Cost effectiveness Maintenance therapy Genes IL23 Ulcerative colitis MARKER Therapeutics Colorectal cancer Colibactin and lipids Gènes Small molecules Résistance Thérapie ciblée Eradication Colectomy Clinical trial Patient-reported outcome Dysbiosis IBD Resistance Colon Disease Progression COLON-CANCER PCR Contraindication Microbiota MALT Drug Fecal microbiota DNA methylation IL12 Anti-TNF agents Gene methylation Anti-TNF Algorithm Parvimonas micra Clinical guidelines Inhibitor Consensus Inclusion Crohn’s disease Colonic epithelial primary cells Inflammatory bowel diseases MORTALITY Surgery Biomarker MICROBIOTA Kidney diseases Bactéries Éradication T1118 translocation Inflammatory Bowel Diseases Vedolizumab Colorectal cancer Heart disease risk factors Eligibility 18 FDG-PET/CT Biologics Tailored therapy Cell adhesion Original Article Clinical Ustekinumab Microbiote Disability Stricture Venous thromboembolism CARCINOGENESIS Immunosuppressant Rituximab plus chlorambucil RISK DNA METHYLATION Intestinal crypts Patients experience Gene expression Cancer Dysbiose Epigenetics Helicobacter pylori Méthylation Bacteria Neoadjuvant chemotherapy Alkylating agents Upper gastrointestinal tract Crohn's disease Primary sclerosing cholangitis Survival Screening Effectiveness Tuberculosis Endoscopic treatment Methylation Epigénétiques Rituximab